Lyra Therapeutics (LYRA) EBT (2019 - 2025)

Lyra Therapeutics has reported EBT for 7 years, with the latest figure at -$6.9 million in Q4 2025.

• On a quarterly basis, EBT rose 36.67% year-over-year to -$6.9 million in Q4 2025; TTM through Dec 2025 was -$28.9 million, a 69.05% increase from a year earlier, with the FY2025 full-year figure at -$28.9 million, up 69.05% from the prior year.
• EBT was -$6.9 million for Q4 2025 at Lyra Therapeutics, down from -$6.0 million in the prior quarter.
• The five-year high for EBT was -$6.0 million in Q3 2025, with the low at -$48.1 million in Q2 2024.
• Average EBT over 5 years is -$14.2 million, with a median of -$12.8 million recorded in 2021.
• The sharpest annual moves came in 2024 and 2025: EBT plunged 208.34% in 2024, then soared 84.55% in 2025.
• Over 5 years, EBT stood at -$13.6 million in 2021, then decreased by 4.44% to -$14.2 million in 2022, then decreased by 6.45% to -$15.1 million in 2023, then rose by 27.52% to -$11.0 million in 2024, then surged by 36.67% to -$6.9 million in 2025.
• The last three EBT figures came in at -$6.9 million (Q4 2025), -$6.0 million (Q3 2025), and -$7.4 million (Q2 2025), per Business Quant data.